Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple MyelomaBusiness Wire • 12/09/22
Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple MyelomaPRNewsWire • 12/09/22
Gilead Sciences, Inc. (GILD) Presents at NASDAQ 47th Investor Conference (Transcript)Seeking Alpha • 12/07/22
New Data for Trodelvy Demonstrate Clinical Efficacy Across Trop-2 Expression Levels in HR+/HER2- Metastatic Breast CancerBusiness Wire • 12/06/22
Gilead Sciences, Inc. (GILD) Management presents at Piper Sandler Healthcare Conference (Transcript)Seeking Alpha • 11/30/22
Gilead Sciences, Inc. (GILD) 2022 5th Annual Evercore ISI HealthCONx Conference(Transcript)Seeking Alpha • 11/30/22
European Commission Grants Expanded Marketing Authorization for Gilead's Biktarvy® for the Treatment of HIV in Pediatric PopulationsBusiness Wire • 11/29/22
These Are the Five Best and Worst Performing Healthcare Stocks in October 202224/7 Wall Street • 11/29/22
Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That SurgesInvestors Business Daily • 11/28/22
Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-small Cell Lung CancerBusiness Wire • 11/28/22
Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-Small Cell Lung CancerBusiness Wire • 11/28/22
Why the 5 Highest-Yielding Nasdaq Stocks Could Rip Higher With a Santa Claus Rally24/7 Wall Street • 11/28/22
See Why Gilead's Cancer Business Is Driving The Stock To A Fever PitchInvestors Business Daily • 11/23/22